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INTRODUCTION
Despite the advancement in cancer therapy, bladder cancer 
remains one of the major challenges leading to worldwide 
cancer-related death [1]. The initial treatment of non-mus-
cle-invasive transitional cell carcinoma of the bladder gener-
ally is a complete cystoscopic resection of all visible tumour 
followed by adjuvant intravesical therapy [2]. Mitomycin C 
(MMC) is one of the most commonly used intravesical che-
motherapeutic agents although its clinical effectiveness is of-
ten limited by high rate of recurrence due to the emergence 
of drug-resistant tumour cells [3-4]. So, multiple approaches 
have been tried to improve efficacy and decrease recurrence 
including increasing the drug concentration and extending 
the dwell time [5].
Sufficient body of evidence has recognized the associa-
tion between bladder cancer, as well as resistance to chemo-
therapy, and the production of abnormal signal transducer 
Ras protein [6]. This association has been early reported in 
T24 bladder cancer cell line where the first human oncogene 
was identified [7]. Mutations in RAS genes can direct the ex-
pression of constitutively active Ras proteins which promote 
the activation of the immediate effector Raf kinase family. 
Once activated, Raf initiates the sequential downstream 
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phosphorylation of MEK and ERK which finally interact 
with transcription factors responsible for cell cycle progres-
sion and proliferation. Locked in the GTP-bound mode, the 
abnormally activated Ras protein triggers incessant activa-
tion of the Raf/MEK/ERK cascade leading to uninterrupted 
cell division and carcinogenesis [8-9]. Overexpression of at 
least 1 of the 3 canonical Ras proteins was found in 77% of 
analyzed bladder tumours [10] while even a single nucleo-
tide polymorphism in the H-Ras locus was associated with 
development of more aggressive types of bladder cancer 
[11]. Ras inhibition was employed as a treatment strategy to 
control cell proliferation, to induce apoptosis and to increase 
the sensitivity of tumour cells to different tumour cell-killing 
agents. The inhibition was targeted at many levels of the Ras/
MAPK signaling circuit [12-13].
Curcumin (CUR) is the principal polyphenolic com-
pound (Fig 1) isolated from the powdered rhizome of tur-
meric (Curcuma longa L.), a member of the ginger family. 
Although several research point at curcumin as having wide 
range of pharmacological activities but clinical studies have 
yielded frustrating results due to its chemical instability 
and poor oral bioavailability [14], however, recent reports 
demonstrated promising anti-tumour effects of curcumin 
against variable types of cancer cells in vitro [15]. The pre-
cise target(s) of curcumin action have remained elusive with 
some reports described its interaction with several signal 
transduction pathways including NF-κB, AKT, Ras/MAPK, 
p53, JAK/STAT and AMPK [16]. Recent observation has also 
shown that modulation of cell signaling pathways through 
the pleiotropic effects of curcumin likely activate cell death 
signals and induce apoptosis predominantly in Ras-activat-
ed tumour cells [17]. On the other hand, we have recently 
shown that silencing the RAS oncogene by small interfering 
RNA (siRNA) reversed the resistance of T24 bladder cancer 
cells to MMC and induced apoptosis when exposed to small 
doses of MMC (0.3 to 10 µg/ml) [18]. Based on this finding 
and other related experiments demonstrating that inhibition 
of Ras decreased resistance and invasiveness of cancer cells 
in vitro, if curcumin can disrupt the Ras/Raf/MEK/ERK sig-
naling pathway, it should reverse Ras-dependent resistance 
of cancer cells to chemotherapeutic agents. Therefore, we 
aimed at investigating the combined effect of curcumin with 
small dose of MMC on the Ras/MAPK-dependent apoptosis 
in T24 bladder cancer cells which were reported earlier to be 
naturally resistant to MMC [19]. We hypothesise that cur-
cumin may induce synergistic tumor cell killing with MMC 
comparable to that previously observed with Ras siRNA, 
consequently, curcumin might be elected as a safe and avail-
able intravesical adjuvant with MMC in clinical trials.
MATERIALS AND METHODS
Cell culture
Human bladder cancer cell line T24, obtained from the Eu-
ropean Collection of Authenticated Cell Cultures (ECACC), 
were grown in confluent monolayers with McCoy’s 5A me-
dium (Sigma-Aldrich Co. Ltd., Poole, Dorset, England) sup-
plemented with 10% fetal calf serum (FCS), 100 U/ml peni-
cillin and 100 µg/ml streptomycin, and maintained at 37 °C 
with 5% CO2. Under these conditions the doubling time was 
9–10 h and cell density of 60–70% confluency on the day of 
experiments. Individual cell suspensions were obtained by 
trypsinization (0.25% trypsin-EDTA) of adherent monolay-
er.
Treatment protocols
Human pan-Ras siRNA targeting all isoforms of Ras and the 
non-targeting negative control siRNA were made up accord-
ing to manufacturer’s instructions (siIMPORTER transfec-
tion kit, Upstate Biotechnology Inc., VA, USA). Curcumin 
(Sigma–Aldrich, St. Louis, MO, USA) was prepared by dis-
solving the pure powder (≥ 80% purity) with dimethyl sulf-
oxide (DMSO) then with 100% ethanol. Subsequently, a se-
ries of diluted concentrations was made up from 0 to 20 µM. 
T24 cells were divided into 5 groups according to treatment 
protocol – group 1 cells were left as blank control (without 
any drug treatment). Group 2 were cells exposed only to 10 
µg/ml MMC (Kyowa Hakko UK Ltd, England) for 1 h then 
washed and incubated with drug free media for 72 h. Group 
3 were cells cultured in media containing different concen-
trations of curcumin (5, 10, 20 µM). Group 4 were cells ex-
posed to 10 μg/ml MMC for 1h then washed and further 
transfected with 50 nM of pan-Ras siRNA and incubated in 
Fig 1. Chemical structure of curcumin (keto form)
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serum free medium for 4h at 37 °C then FCS was added and 
cells were incubated for 72h. Group 5 were cells exposed to 
MMC for 1 h then washed and incubated for 72 h with new 
media containing the previous concentrations of curcumin. 
A full set of controls were used to detect false negative and 
false positive results. The final concentration of DMSO for 
all experiments was maintained at less than 0.1%. These con-
centrations were previously reported to be non-cytotoxic for 
72 h [17]. 
Cell proliferation assay
The anti-proliferative potential of treatments was assessed by 
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) tetrazolium reduction test according to 
the manufacturer’s instructions (Abnova, USA). Cells were 
seeded at 5 × 103 cell density in a 96-well tissue culture plate 
and left to attach for 24 h at 37 °C with 5% CO2 then fresh 
media containing different drug treatments were added and 
incubated for 72 h. Four h prior to the end of the 72 h incu-
bation period with treatments, 20 µl of MTT solution (5 mg/
ml PBS) was added to each well and incubated at 37 °C to the 
end of the 72 h. After 4 h, all media were removed and the 
insoluble purple formazan crystals were dissolved by adding 
200 µl DMSO to each well and incubated in the dark for ad-
ditional 30 min. The absorbance was read at 590 nm using 
a spectrophotometric plate reader. The relative percentage 
of viable cells was calculated from triplicate measurements 
using the background-corrected absorbance as follows [20]: 
% viable cells=(Mean absorbance of test samples)/(Mean ab-
sorbance of negative controls) x 100
Assessment of apoptosis and cell cycle 
analysis
Tumour cells were fixed in 70% alcohol for 1h and stained 
with Giemsa and H&E. Architectural features described the 
overall arrangement of the cell sheets and the extent of cell 
loss, mitotic activity, apoptotic count, and the most preva-
lent apoptotic stage were assessed morphologically on a set 
of three slides using the X40, X100 and X400 objectives on a 
Leica DM2500 microscope (Leica, Germany) equipped with 
high resolution DC300 Leica camera. Progression of cells 
through the cell cycle and cell apoptosis were measured by 
propidium iodide (PI)/fluorescence-activated cell analysis of 
subGo/G1 DNA content as follows – after fixation in 70% 
alcohol for 1h, cells were washed and suspended in 1 ml of 
fluorescent probe solution containing PBS, 1% Triton X-100, 
50 µg/ml PI and 0.5 mg/ml RNase for 30 min in the dark at 
room temperature. Ten thousands events were acquired us-
ing a Coulter EPICS Elite flow cytometer (Beckman Coulter, 
FL, USA) and cells were discriminated according to levels of 
red fluorescence collected via 610 nm long band pass filter. 
DNA histograms were analyzed using WinCycle version 3.0 
(Phoenix Flow Systems, San Diego, USA).
Immunocytochemistry (ICC)
Alcohol-fixed cells were washed prior to immunostaining 
using 5 µg/ml of anti-pan-Ras (clone Ras10, Upstate, VA, 
USA) and 1 µg/ml of mouse polyclonal ERK which reacts 
with both ERK1/2 (Santa-Cruz Biotechnology, Santa-Cruz, 
CA) or matched isotypes IgG2a (Ras) and IgG1 (ERK) at 
equivalent concentrations diluted in PBS with 0.04% Tween 
80 (PBST). Immunoreactivity was visualised using HRP 
Mouse (DAB+) EnVision Kit (Dako). Computer-aided 
quantification of ICC staining was performed based on the 
principle described before [21] with slight modification [22]. 
Briefly, digital images were acquired at X100 using Leica dig-
ital camera and analyzed with VideoTesT-Morphology soft-
ware (Russia). Color sampling representing Ras and ERK1/2 
staining was selected and the number of selected pixels was 
read from the histogram of colours and their percentage per 
section was calculated. Ten random images from each slide 
were analyzed and averaged.
Western blotting 
After trypsinization and centrifugation, washed cell pellets 
were lysed for 15 min on ice using 300 µl of CelLytic-M 
mammalian reagent (Sigma-Aldrich, UK) followed by cen-
trifugation at 15,000 x g for 20 min at 4 °C. Soluble protein 
concentration in the supernatant was determined using 
Pierce BCA Protein Assay kit and instructions (Thermo Sci-
entific, USA). Aliquots of 15 μg of denaturated and reduced 
protein were resolved on NuPAGE Novex 4–12% Bis-Tris 
Gels (Invitrogen, USA) by SDS-PAGE prior to transfer onto 
nitrocellulose membrane (Bio-Rad Lab., USA). After incu-
bation in blocking buffer (5% non-fat milk in TBST) for 2 h 
at room temperature, membranes were incubated overnight 
at 4 °C with mouse monoclonal antibodies (Santa Cruz Bio-
tech., Santa Cruz, CA, USA) against pan-Ras, pERK1/2, 
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and  β-actin followed by incubation with horseradish per-
oxidase-conjugated secondary anti-mouse IgG (1:1000; San-
ta-Cruz) for 1 h at room temperature. After three washes in 
PBS with 0.1% Tween-20, Images were digitized using View-
Pix 700 gel scanner and analyzed by TotalLab software (To-
talLab Ltd. UK).
Statistical analysis
The statistical analysis was performed using SPSS 15.0 (SPSS 
Inc., Chicago, IL, USA). Data were quantified from triplicate 
measurements and were represented as mean ± SD. Multiple 
comparison between means was performed using the one-
way analysis of variance (ANOVA) followed by Tukey post 
hoc test. A P-value of less than 0.05 was considered statisti-
cally significant.
RESULTS
T24 cells sensitivity after single MMC or 
curcumin treatment
Untreated T24 cells grew in irregularly dispersed sheets con-
taining cells of varying size and shape. As expected, MMC 
treatment caused significant architectural disruption, in-
crease in apoptotic bodies, and reduction of mitotic indices 
observed after 24 h and reached the maximum after 72 h. 
There was no significant changes in cells grew in 5 µM of 
curcumin while there were progressive architectural disrup-
tion, increase in apoptotic bodies, and reduction of mitotic 
indices started to show with 10  and 20 µM curcumin after 
72 h as compared with non-treated cells (P<0.05 and P<0.01 
respectively, Fig 2). Cell proliferation assay revealed 38% re-
duction of cell viability after exposure to 10 µg/ml MMC. 
There was also dese-dependent reduction of cell viability 
with 10 and 20 µM curcumin alone (P<0.05, Fig 3).
Flow cytometric analysis revealed 4.0 fold increase in the 
mean subGo/G1 events after 72 h in MMC-treated cells as 
compared with blank controls (32.1 ± 5.12 compared with 
7.84 ± 2.15 in non-treated cells, P < 0.01, Fig 4). There was 
1.4 fold increase in the mean subGo/G1 events after 72 h in 
20 µM curcumin-treated cells (15.32 ± 3.52 compared with 
7.84 ± 2.15 in non-treated cells, P < 0.05, Fig 4). 
As analyzed with computer image analysis, the intensi-
ty fraction of Ras and ERK1/2 immunostaining decreased 
progressively after 72 h from 26.78% ± 4.17 and 22.38% ± 
3.65 in non-treated cells to 17.49% ± 3.42 and 14.81% ± 3.02 
respectively after MMC treatment (P < 0.01 and P<0.05 re-
spectively). Likewise, both Ras and ERK1/2 immunostaining 
were significantly reduced with 10 and 20 µM, but not with 
Fig 2. Morphology of T24 cells 
as seen with different treatments 
after 72 h. (A) Untreated cells; (B) 
Cells treated with 10 µg/ml MMC 
showing significant architectural 
disruption; (C) Cells treated with 
5 mM CUR showing minimal 
morphological changes; (D) Cells 
treated with 20 mM CUR showing 
significant architectural disruption 
with some apoptotic bodies; (E) 
Cells treated with 10 µg/ml MMC 
for 1 h then washed and transfected 
with 50 nM Pan-Ras siRNA and 
cultured for 72 h; (F, G, H) Cells 
treated with 10 µg/ml MMC for 1 h 
then washed and further cultured 
with 5, 10, and 20 µM CUR. There 
is dose-dependent decrease in 
cellularity with disruption of normal 
architecture. The arrows indicate 
apoptotic cells (Giemsa X200).
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up to 5 µM, of curcumin (P < 0.05, Fig 5 and 6). Western blot 
analysis revealed significant reduction of Ras and phosphor-
ylated ERK1/2 expression in MMC and curcumin (10 and 
20 µM)-treated cells as compared with non-treated controls 
(Fig 7).
T24 cells sensitivity after combined 
treatments
Morphological examination of Ras siRNA transfected T24 
cells were compared to other control slides for better charac-
terization of the effect of Ras inhibition on cells phenotype. 
Due to the significant cell death induced in T24 cells follow-
ing the individual use of high concentrations of Ras siRNA 
observed in our previous study [18], low dose of Ras siRNA 
(50 nM) was used with MMC in the synergy experiment. As 
shown in Fig 2, at the end of 72 h culture time, the morpho-
logical picture of T24 cells treated with 10 µM of MMC in 
synergy with 50 nM Ras siRNA showed greater architectural 
disruption, increased apoptotic bodies, and reduced mitotic 
indices than those exposed to MMC alone. The overall mor-
phological picture of T24 cells treated with combined MMC 
and 20 µM of curcumin, including significant architectural 
Fig 3. Cell viability percentage as assessed by MTT assay after 72 h 
culture with different treatments. The maximum inhibition was 
observed with combined MMC 10 µg/ml and 50 nM Ras siRNA. A 
dose-dependent inhibition of cell viability was observed with CUR 
treatments. Combination of MMC plus CUR exerted significant 
inhibition as compared with MMC alone. Significance levels: *P<0.05; 
**P<0.01; ***P<0.001 vs untreated control. #P<0.05 vs MMC alone 
(ANOVA of triplicate samples).
Fig 4. Flow cytometric illustrations of SubGo/G1events in T24 cells after 72 h culture with different treatments. (A) Untreated T24 cells; (B) Cells 
treated with 10 µg/ml MMC; (C, D, E) Cells treated with 5, 10, and 20 µM CUR respectively; (E, F, G) Cells treated with 10 µg/ml MMC for 1 h 
followed by culture with 5, 10, and 20 µM CUR respectively for 72 h. The DNA histograms illustrate an increase in percentage of subG1 events after 
MMC treatment. There is also dose-dependent increase of subG1 events in response to solitary CUR treatment. The apoptotic events are increased 
dose-dependently in cells treated with binary MMC and CUR treatment which are significantly higher than with MMC alone. Error bars are the 95% 
confidence limits of triplicate results. Significance levels: *P<0.05; **P<0.01; ***P<0.001 vs untreated control.
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disruption, number of apoptotic bodies and reduction of mi-
totic index, was comparable to this seen in cells treated with 
MMC and further knocked down with 50 nM Ras siRNA 
(Fig 2). Slight, but significant, changes were observed when 
10 µM of curcumin was used, while lower concentrations of 
curcumin (5 µM) did not show synergistic effects.
Cell viability/cytotoxicity assessed with MTT assay 
showed greater reduction of cell proliferation/viability (68%, 
P<0.001) after transfection with 50 nM Ras siRNA follow-
ing MMC exposure. Significant inhibition was also observed 
in cells treated with combined MMC and 20 µM curcum-
in as compared with MMC alone (58%, P<0.001 vs control; 
P<0.05 vs MMC alone, Fig 3). In addition, the conjoined 
treatment with 10 µg/ml MMC and 50 nM Ras siRNA pro-
voked significant increase of subG/G1 events when com-
pared to the number induced by single treatment with MMC 
alone (49.6 ± 5.23 compared with 32.1 ± 5.12, P<0.05). There 
was significant dose-dependent increase in subG/G1 events 
with 5, 10 and 20 µM curcumin when combined with MMC 
as compared with MMC alone (P<0.05, P<0.01, P<0.001 re-
spectively, Fig 4).
The decrease of the intensity of Ras and ERK1/2 immu-
noreactivity recognized by ICC image analysis after com-
bined MMC and Ras siRNA treatment was significantly 
greater than that observed after MMC treatment alone (Fig 5 
and 6). Ras and ERK1/2 immunostaining fraction decreased 
progressively after 72 h from 17.49% ± 3.42 and 14.81% ± 
3.02 in MMC-treated cells to 9.64 ± 2.37 and 7.44 ± 2.41 re-
spectively (P<0.05 for both) in cells treated with combined 
MMC and 50 nM Ras siRNA. Likewise, the decrease of the 
intensity of Ras and ERK immunostaining recognized by 
IHC image analysis after combined MMC and curcumin (10 
and 20 µM) treatments were significantly greater than that 
observed after MMC treatment alone (Fig 5 and 6). Ras and 
ERK1/2 immunostaining showed progressive decrease with 
the maximum inhibition seen with 20 µM dose of curcum-
in (10.31 ± 2.42 and 8.37 ± 2.11 respectively in MMC plus 
curcumin compared to 17.49% ± 3.42 and 14.81% ± 3.02 in 
MMC alone, P<0.05 for both). Western blot studies also con-
firmed these results (Fig 7).
DISCUSSION
Transurethral resection followed by intravesical installation 
of chemotherapy remains the preferred choice in the man-
agement of non-muscle invasive bladder cancer [2]. MMC 
is an anticancer drug that is used intravesicaly in the man-
agement of bladder cancer. However, tumor cell resistance 
to this agent remains the main obstacle in successful can-
cer therapy, therefore, novel therapeutic combination treat-
ments are required to improve chemoresponsiveness. The 
tumorigenic role of Ras/MAPK pathway in T24 cells can 
afford key information to our understanding as to why 30-
60% of bladder tumors expressing mutated Ras protein have 
Fig 5. Total protein Ras expression in T24 cells after 72 h of culture 
with different treatments. (A) untreated cells; (B) Cells treated with 10 
µg/ml MMC showing reduced Ras protein expression possibly due to 
depletion of the protein forming capacity after DNA damage; (C) Cells 
treated with 5 µM CUR showing modest change of Ras expression; (D) 
Cells treated with 20 µM CUR showing significant reduction of Ras 
protein; (E) Cells treated with MMC for 1 h then transfected with 50 
nM of Ras siRNA showing significant architectural disruption with 
great knockdown of Ras expression; (F, G,H) Cells treated with 10 
µg/ml MMC for 1 h followed by culture with 5, 10, and 20 µM CUR 
respectively. These cells demonstrate progressive and concentration-
dependent inhibition of Ras expression. Cells undergoing apoptosis 
are stained dark (arrows, X400).
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tendency to develop tumor invasiveness and resistance [23]. 
It is now established that activated Ras-GTP triggers mito-
genic signaling and ultimately leading to activation of tran-
scriptional ERKs [24]. The activated Ras/Raf/ERK-signaling 
pathway creates a robust proliferative stimulus that leads to 
uncontrolled cell division [25-26]. In a previous study [18], 
we have shown that knocking down the Ras oncogene result-
ed in enhanced MMC-induced chemosensitivity and apop-
tosis in T24 cells which has been previously reported to be 
MMC-resistant [19].
Conclusion of synergism between drug combinations 
should be investigated carefully. Ideal synergism should 
involve positive interaction between the two drugs on one 
common target by exerting different mechanisms of action. 
Alkylation of DNA is the most favoured mechanism of ac-
tion for MMC, but other modes of action, such as inhibition 
of rRNA and redox cycle interference, may also contribute 
to the biological action of the drug [27]. The understanding 
of the appropriate dose and duration of MMC exposure was 
acquired from our previous study which proved that MMC 
treatment using low concentrations over 72 h was the best 
combination regimen with Ras siRNA. This pre-rationale as-
sessment strategy meant that the siRNA treatment protocol 
was based on a substantial background and information of 
how the proteins worked in response to individual agents. 
This was particularly important because the “hit” of the sec-
ond therapy could be scheduled to coincide with the lowest 
expression of the target. Data presented herein have shown 
that T24 cells express more Ras, supporting previous reports 
that Ras expression was associated with tumor cell resistance 
[28]. We observed that both Ras and ERK1/2 immunoreac-
tivity in T24 cells was decreased 72h after treatment with 
MMC, and this could be perceived in light of depletion of 
the protein synthesis capacity in T24 cells after 72h. These 
data suggest that Ras siRNA would be most effective 72h af-
ter treatment with low concentrations of MMC. 
In our previous study [18], we used MMC in low and 
high concentrations (up to 100 μg/ml) in combination with 
two different concentrations of Ras siRNA, and we found 
that Ras siRNA sensitized T24 cells to apoptosis induced by 
Fig 6. ERK1/2 expression in T24 cells after 72 h of culture with different 
treatments. (A) Untreated cells expressing more ERK; (B) Cells treated 
with 10 µg/ml MMC showing reduced ERK expression possibly due to 
depletion of the protein forming capacity after DNA damage; (C, D, F) 
Cells treated with 10 µg/ml MMC for 1 h followed by  5, 10, and 20 µM 
CUR respectively. There is progressive and concentration-dependent 
inhibition of ERK expression in response to CUR treatment (X200).
Fig 7. Western blotting of Ras and pERK1/2 protein expression in 
T24 cells after 72 h of culture with different treatments. The levels of 
Ras and pERK1/2 following 50 nM Ras siRNA were low compared to 
untreated cells. There was progressive decrease of the blot thickness 
and intensity with increasing doses of CUR. Ras bands appeared at 
the standard Ras molecular weight of 20 KDa while pERK1/2 bands 
appeared between 42 and 44 kDa when compared with the molecular 
weight β-actin marker.
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MMC at concentration ranges from 0.3 to 10 μg/ml which 
proved previously to be insufficient to induce significant 
cytotoxicity. In this study, we used only the 10 μg/ml as a 
standard concentration reported to possess the median cy-
totoxic effect. We used Ras siRNA to break the resistance of 
T24 cells to MMC through inhibition of Ras-dependent re-
sistance. Combination between MMC and Ras siRNA was 
employed as a reference synergy experiment.
Several studies have pointed at the proficiency of the 
natural compound curcumin to have antitumor activity and 
enhance chemosensitivity of cancer cells to cytotoxic com-
pounds, For instance, curcumin reverses cisplatin resistance 
in cervical cancer cells [29], breast cancer cells [30], and re-
duces multidrug resistance in human colon cancer cells [31]. 
However, the exact mechanism and/or molecular targets of 
curcumin remain elusive. So, we hypothesized that curcum-
in might act through the inhibition of the Ras/MAPK path-
way, and accordingly, could be matched with Ras siRNA as 
combination strategy with MMC on T24 cells. The data pre-
sented herein demonstrate that curcumin at concentrations 
of 10 and 20 μM, alone, exerted antitumor activity against 
T24 cells as shown from decreased cellularity, inhibited 
proliferation and increased apoptotic signals in a dose-de-
pendent manner. Likewise, curcumin reversed resistance of 
these cells to 10 μg/ml MMC as did specific knocking down 
the Ras oncogene with Ras siRNA. Curcumin-treated cells 
showed reduced Ras protein expression along with reduced 
both ERK1/2 and its phosphorylated form, the two canon-
ical proteins of the MAPK pathway. This reduction of cru-
cial MAPK proteins coincided with significant morpholog-
ical architectural disintegration and increased frequency of 
subG0/G1 apoptotic events, so, at this point we can confirm 
that curcumin-related cytotoxicity is, at least partially, de-
pendent on inhibition of the Ras/MAPK signaling pathway. 
ERK is the straight downstream MAPK effector respon-
sible for cell resistance to apoptosis, and therefore acts as 
indicator of Ras activation and expression levels [32]. To 
further study the effects of combined MMC and Ras siR-
NA knockdown, a set of experiments employing antibodies 
against the two isozymes ERK1/2 were considered. Sever-
al studies have shown that Ras activates a number of sig-
nal transduction pathways, including the Raf/MEK kinase 
pathway [33]. In the present study, 10 and 20 micromolar 
concentrations of curcumin, either alone or in combination 
with MMC decreased immunoreactivity of ERK1/2 and 
their phosphorylated forms together with increased apop-
tosis as did combination of 50 nM Ras siRNA with MMC, 
Meanwhile, MMC alone was associated with only minor 
apoptosis. Hence the combination of MMC with curcumin 
was synergistic and achieved the utmost inhibition of Ras 
synthesis and ERK expression. The combination of DNA al-
kylation by MMC and withdrawal of proliferation factors by 
curcumin achieved synergistic effect through targeting dif-
ferent pathways of apoptotic resistance. This finding high-
lights the necessity to investigate combination therapies that 
interfere with two pathways or intended to hit one pathway 
and its linking feedback loop. 
In conclusion, this study indicates that resistance of T24 
cells to cytotoxic effect of MMC is dependent, at least par-
tially, on Ras/ERK activation. We have demonstrated that 
curcumin at concentrations of 10 and 20 μM in combina-
tion with low dose MMC induced toxic synergism in T24 
cells. Clinical translation of this experimental study may be 
reasonable in light of wide safety margin and availability of 
curcumin which elect it as a safe and valuable intravesical 
adjuvant with MMC in management of superficial bladder 
cancers.
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